Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 8/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.51 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663392 | 1.00 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL4692556 | 0.83 | MAP4K4 (0.66) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL29713890 | 0.83 | MAP4K4 (0.66) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| Water SCHEMBL28851833 | 0.81 | MAP4K4 (0.64) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| Hydrochloric Acid SCHEMBL10969363 | 0.81 | MAP4K4 (0.64) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL2082154 | 0.79 | EGFR (0.51) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL22911854 | 0.79 | PDE4A (0.53) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL20813473 | 0.79 | EGFR (0.53) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL6442231 | 0.79 | NR4A2 (0.56) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL7376295 | 0.79 | MAP4K4 (0.54) | PI4KAPI4K2BPI4K2API4KBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4269395-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2023-11-01 | — | — | EP | claimed |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-12-29 | — | — | US | disclosed |
| US-11447492-B2 | ERBB receptor inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| EP-2934538-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | PI4KA 3516/4885PI4K2B 3865/4885PI4K2A 4617/4885 |
| US-11447492-B2 | ERBB receptor inhibitors | ERBB2, EGFR, ERBB3 | PI4KA 491/4885PI4K2B 730/4885PI4K2A 714/4885 |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | ERBB2, EGFR, ERBB3 | PI4KA 495/4885PI4K2B 614/4885PI4K2A 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.